Navigation Links
InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
Date:9/13/2010

  • 10:00 a.m. -- Percent predicted forced vital capacity is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (Ron du Bois, M.D.)

  • About Pirfenidone

    InterMune has submitted a Marketing Authorization Application (MAA) seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, which was validated by the European Medicines Agency (EMA) effective March 24, 2010. Validation of the MAA by the EMA indicates that the application is complete and that the review process has begun.

    IPF is a rare and fatal lung disease that affects approximately 200,000 people in the United States and Europe combined. If approved by the EMA, pirfenidone would be the first medication to be made available to IPF patients in the European Union. Pirfenidone has been granted Orphan Drug designation in Europe.

    Preclinical and in-vitro evidence has shown that pirfenidone has both anti-fibrotic and anti-inflammatory effects. In February 2009, InterMune announced the results of the company's two global Phase 3 clinical trials evaluating pirfenidone for the treatment of IPF, known as the CAPACITY trials. Prior to the CAPACITY results, Shionogi & Co. Ltd (Shionogi) had presented data from a Phase 3 study conducted in Japan which demonstrated that pirfenidone reduced the decline in lung function and improved progression-free survival in patients with IPF. In this clinical study, pirfenidone was safe and generally well-tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi in that country.

    About InterMune

    InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. InterMune to Release Second Quarter Financial Results on July 27
    2. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
    3. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
    4. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
    5. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
    6. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
    7. InterMune to Present at Deutsche Bank Biotech Confab
    8. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
    9. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
    10. InterMune to Present at JMP Securities Conference
    11. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... NEW YORK , Sept. 2, 2015 ... leukemia is a malignant condition characterized by increased production ... first affects B-lymphocytes and then it can spread to ... mostly at later stages because of the slow buildup ... disease, the malignancy spreads to the spleen, liver, and ...
    (Date:9/2/2015)... --  Physicians Rx Pharmacy ("PRxP") today announced that ... as President and Chief Executive Officer.  Mr. ... Executive Officer for Soleo Health Specialty Infusion Services, will, ... Pharmacy, be responsible for leading the rapidly-growing 340B pharmacy ... bring Gaston on as the President and CEO of ...
    (Date:9/2/2015)... Calif. , Sept. 2, 2015 ... submission of a Marketing Authorization Application (MAA) to ... procedure for etelcalcetide (formerly AMG 416) for the ... with chronic kidney disease (CKD) on hemodialysis therapy. ... agent that can be administered intravenously. ...
    Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7
    ... Today, the senior advocacy group RetireSafe notified the Senate in ... SA 2793. , RetireSafe President Thair Phillips said, "Senator ... our safe, closed drug system to be breached, and our ... supporters will be watching closely the vote on this amendment ...
    ... , MOUNTAIN VIEW, Calif., Dec. 10 ... performance-driven, online marketing and distribution company, announced today that ... Concepts Holdings, Inc. (MDHI.OB) to market and provide lead ... as MediPendant(TM). , MediPendant(TM) is the first ...
    Cached Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3
    (Date:9/2/2015)... Jose, CA (PRWEB) , ... September 02, 2015 ... ... for Internet of Things, announces its latest addition to its screen mirroring and ... existing award-winning Splashtop Extended Wireless Display, which operates in local WIFI setting, the ...
    (Date:9/2/2015)... ... ... The medical waste management market is expected to reach USD 13.3 billion by 2020 ... waste management market is segmented based on type of waste, services, treatment type, treatment ... growth rate in the medical waste management market, by service, during the forecast period. ...
    (Date:9/2/2015)... ... September 02, 2015 , ... A ... partnership has earned international recognition as a premier center for treatment of and ... sudden, catastrophic internal bleeding and stroke. , Cure HHT, previously known as ...
    (Date:9/2/2015)... , ... September 02, 2015 , ... ... Center at Children's Healthcare of Atlanta to help support childhood cancer research. ... the upcoming WSB Radio Care-A-Thon , which is the fund-raising event DoMyOwnPestControl.com ...
    (Date:9/2/2015)... ... 02, 2015 , ... A third party administrator (TPA) based ... a significant increase in unlawful tactics used by out-of-network (OON) ambulatory surgical centers ... OON ASCs encouraging members to have elective procedures done at their facilities with ...
    Breaking Medicine News(10 mins):Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 2Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 3Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 4Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 5Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3
    ... Corporation,(Nasdaq: PODD ), the manufacturer and marketer ... Duane DeSisto, Chief Executive,Officer, will participate in the ... to present an overview of the Company,at 1:30 ... at The Westin St.,Francis Hotel in San Francisco., ...
    ... Officer of Aetna, Inc., LOVELAND, Colo., Jan. ... announced that Ms. Louise McCormick has joined the,company,s ... "We pride ourselves on our commitment to ... high quality, independent Directors,is critical to this effort," ...
    ... chances of damage to areas that control language , , WEDNESDAY, ... enable surgeons to perform brain surgery with less damage to ... As a bonus, brain researchers may also get a more ... , The new technique, described in the Jan. 3 issue ...
    ... ANN ARBOR, Mich. One in four Americans in the ... them will get a urinary tract infection from that catheter. ... life-threatening complications. , And with every new case, UTIs ... for 40 percent of infections related to hospitalization. , ...
    ... Tenn.Obese people are less likely to use their seatbelts ... public health risks associated with this rapidly growing problem. ... psychologist David Schlundt and his colleagues at Meharry Medical ... weight goes up, seatbelt use goes down, Schlundt, associate ...
    ... cancer in the bulls eye. , Cancer really comes from us, ... scary reality that cancer cells are our own cells gone awry. ... horrific invader. , Tumors and T cells, the cellular arm of ... for many years before the tumor grows, says Dr. He, who ...
    Cached Medicine News:Health News:Louise McCormick Joins Heska's Board of Directors 2Health News:Louise McCormick Joins Heska's Board of Directors 3Health News:Scientists Report Refinements to Brain Surgery 2Health News:Catheter chaos: Hospitals lag in preventing common infection 2Health News:Catheter chaos: Hospitals lag in preventing common infection 3Health News:Catheter chaos: Hospitals lag in preventing common infection 4Health News:Obesity linked to decreased seatbelt use 2Health News:New strategies work to put cancer on the firing line 2Health News:New strategies work to put cancer on the firing line 3
    ... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
    ... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
    ... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
    ... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
    Medicine Products: